"Reevaluating KTP as a Treatment for Parkinson's: A Critical Study"
A new study challenges the use of the KTP molecule as a potential treatment for Parkinson's disease, overturning over a decade of thinking. The study found that KTP cannot activate the PINK1 protein due to its size, debunking previous research. The findings suggest that kinetin must be activating PINK1 through a different mechanism, prompting the search for other potential compounds to treat Parkinson's disease.